An eco-friendly NP flame retardant for durable flame-retardant treatment of cotton fabric.

A halogen-free, formaldehyde-free, efficient, durable, NP flame retardant, the ammonium salt of meglumine phosphoric ester acid (ASMPEA), was prepared. The Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance spectroscopy (1H NMR, 13C NMR, and 31P NMR) results indicated that ASMPEA was grafted onto cotton fibers by P-O-C covalent bonds. The LOI value of 30 wt% ASMPEA-treated cotton fabric was 40.2%, and after 50 laundering cycles (LCs), the LOI value decreased to 29.4%, indicating that the cotton fibers treated with ASMPEA were endowed with excellent durable flame retardancy. Thermogravimetry (TG), cone calorimetry, and vertical flammability test results showed that ASMPEA-treated cotton decomposed into phosphoric acid or polyphosphoric acid during combustion, which promoted the thermal degradation and charring of treated cotton fabrics and hindered the spread of flames. Scanning electron microscopy (SEM), X-ray diffraction (XRD), and energy-dispersive spectrometry (EDS) verified that ASMPEA infiltrated the cotton fiber without obviously affecting its surface morphology or crystal structure; however, the mechanical properties of the treated cotton fabric decreased slightly. These results confirm that ASMPEA achieved excellent durable flame retardancy when used to coat cotton fabric.

Development of rebamipide-loaded spray-dried microsphere using distilled water and meglumine: physicochemical characterization and pharmacokinetics in rats.

In this study, a novel rebamipide-loaded spray-dried microsphere (RSM) with enhanced drug solubility and oral bioavailability has been developed utilizing meglumine, an alkalizing agent. The influence of carriers on the drug solubility alone, and the solubility and dissolution of the drug in the RSM was investigated. Among the alkalizing agents and hydrophilic polymers tested, meglumine and polyvinyl alcohol (PVA) showed the highest drug solubility and dissolution rate, respectively. Many RSMs were manufactured with various amounts of meglumine and PVA using distilled water, and their drug solubility and dissolution were determined. The physicochemical properties, dissolution and pharmacokinetics of the chosen RSM in rats were assessed compared to the rebamipide powder and commercial tablet. Among the RSMs tested, the one composed of rebamipide, meglumine and PVA at a weight ratio of 3:1.75:6 showed the highest drug solubility and dissolution. This RSM with a smooth spherical form significantly decreased the particle size and modified the amorphous rebamipide. Furthermore, the drug solubility, dissolution, plasma concentrations, AUC and Cmax values of RSM were significantly higher than those of drug powder and commercial tablet. Thus, this RSN system developed with distilled water and meglumine is recommended as an oral water-soluble rebamipide-loaded pharmaceutical product.

Meglumine-based supra-amphiphile self-assembled in water as a skin drug delivery system: Influence of unfrozen bound water in the system bioadhesiveness.

Hexagonal liquid crystals and supramolecular polymers from meglumine-based supra-amphiphiles were developed as drug delivery systems to be applied on the skin. The influence of fatty acid unsaturation on the structure and mechanical properties was evaluated. Moreover, we have investigated the system biocompatibility and how the type of water could influence its bioadhesive properties. Meglumine-oleic acid (MEG-OA) was arranged as hexagonal liquid crystals at 30-70 wt% water content, probably due to its curvature and increased water solubility. Meglumine-stearic acid (MEG-SA) at 10-80 wt% water content self-assembled as a lamellar polymeric network, which can be explained by the low mobility of MEG-SA in water due to hydrophobic interactions between fatty acid chains and H-bonds between meglumine and water molecules. Both systems have shown suitable mechanical parameters and biocompatibility, making them potential candidates to encapsulate therapeutic molecules for skin delivery. Moreover, a strong positive correlation between the amount of unfrozen bound water in meglumine-based systems and the bioadhesion properties was observed. This work shows that a better understanding of the physicochemical properties of a drug delivery system is extremely important for the correlation with the desired biological response and, thus, improve the product performance for biomedical applications.

Evaluating the complexation behavior and regeneration of boron selective glucaminium-based ionic liquids when used as extraction solvents.

Glucaminium-based ionic liquids are a new class of solvents capable of extracting boron-species from water with high efficiency. The complexation behavior of these ILs with borate was thoroughly studied using (11)B NMR. Two different complexes, namely, monochelate complex and bischelate complex, were observed. (11)B NMR was used extensively to determine the formation constants for monochelate and bischelate complexes. The IL concentration was observed to have a significant effect on the IL-borate complexes. Using an in situ dispersive liquid-liquid microextraction (in situ DLLME) method, the extraction efficiency for boron species was increased dramatically when lithium bis[(trifluoromethyl)sulfonyl]imide (LiNTf(2)) was used as the metathesis salt in an aqueous solution containing 0.1M sodium chloride. IL regeneration after extraction was achieved using 0.1M hydrochloric acid. The extraction efficiency of boron species was consistent when the IL was employed after three regeneration cycles. The selectivity of the IL for boron species in synthetic seawater samples was similar to performing the same extraction from Milli-Q water samples.

Synthesis of glucaminium-based ionic liquids and their application in the removal of boron from water.

A novel class of ionic liquids (ILs), exhibiting high selectivity towards boron species as well as the ability to phase separate from water, were synthesized from N-methyl-D-glucamine. The complexation of boric acid/borate with the ILs was confirmed using (11)B NMR.

Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.

The need for daily parenteral administration represents one of the most serious limitations in the clinical use of pentavalent antimonials against leishmaniasis. In this work, we investigated the ability of beta-cyclodextrin to enhance the oral absorption of antimony and to promote the oral efficacy of meglumine antimoniate against experimental cutaneous leishmaniasis. The occurrence of interactions between beta-cyclodextrin and meglumine antimoniate was demonstrated through the changes induced in the spin lattice relaxation times of protons in both compounds. When free and complexed meglumine antimoniate were given orally to Swiss mice, plasma antimony levels were found to be about three times higher for the meglumine antimoniate-beta-cyclodextrin complex than for the free drug. Antileishmanial efficacy was evaluated in BALB/c mice experimentally infected with Leishmania amazonensis. Animals treated daily with the complex (32 mg of Sb/kg of body weight) by the oral route developed significantly smaller lesions than those treated with meglumine antimoniate (120 mg of Sb/kg) and control animals (treated with saline). The effectiveness of the complex given orally was equivalent to that of meglumine antimoniate given intraperitoneally at a twofold-higher antimony dose. The antileishmanial efficacy of the complex was confirmed by the significantly lower parasite load in the lesions of treated animals than in saline-treated controls. This work reports for the first time the effectiveness of an oral formulation for pentavalent antimonials.

Synthesis and receptor binding affinity of cholecystokinin receptor ligands: 2-and 1-indolyl derivatives of PD134308.

The synthesis of two "dipeptoids" structurally related to the CCK-B antagonist CI-988 (PD134308) is described. The 2- and 1-indolyl derivatives 4a, b were prepared in order to define the role of the tryptophan moiety in this series of "dipeptoids". They were evaluated as competitors in the binding of [3H]-CCK8S on guinea pig brain CCK-B receptors.

'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors.

A drug design strategy to non-peptide small molecule antagonists of neuropeptides is described that targets the molecular diversity which exists in the 'privileged' data set of the physico-chemical properties represented by the side-chains of the 20 genetically encoded amino acids. The strategy is exemplified by the design of a selective and high affinity cholecystokinin CCK-A antagonist PD 140548, CCK-B antagonist CI-988 (formerly PD 134308) tachykinin NK-1 antagonist PD 154075 and NK-2 antagonist Cam-2291. The NK-3 antagonists, PD 157672 and the non-peptide PD 161182, were developed from an information-rich dipeptide library constructed from 256 N-protected dipeptides and 64 hydrophobic biased dipeptides.

Conformationally restricted analogues of the potent CCK-B antagonist CI-988.

The synthesis and structure-activity relationships (SAR) for a series of conformationally restricted analogues of the selective cholecystokinin (CCK) antagonist CI-988 and some closely related analogues are described. A series of appropriately substituted cis- and trans-amino decalins are prepared that mimic the through bond distances between the functional groups in the parent compound CI-988 whilst restricting bond rotation. This strategy has led to conformationally more rigid derivatives that have increased CCK-B receptor binding affinity.

Liposome formation from synthetic polyhydroxyl lipids.

The preparation of liposomes from synthetic dialkyl amphiphiles is described. Two of these lipids were synthesised with mixed chains of 18:0,14:0 and 18:0,22:0 and one contained two identical alkyl chains of 18:0,18:0. Based on electron microscopic observations and encapsulation studies, liposomes formed from these lipids resemble those prepared from natural lipids. The polyhydroxyl head group of these lipids was designed to mimic the oligosaccharide rich surface of natural cells. SPLVs of all lipid compositions investigated, had higher encapsulation efficiency compared with that of MLVs. With SPLVs the encapsulation efficiency obtained with EPC liposomes were similar to those with novel lipids. However, the optimum was obtained with 4a:cholesterol. Encapsulation efficiency in both MLVs and SPLVs was higher with novel lipid containing different side chain length.

N-alkyl-N-dithiocarboxy-D-glucamine analogs as cadmium antagonists: synthesis and evaluation of the n-propyl, n-butyl, and n-amyl derivatives.

N-(n-Propyl)-, N-(n-butyl)-, and N-(n-amyl)-N-dithiocarboxy-D-glucamine were newly synthesized by (a) addition of each n-alkylamine to glucose, (b) high-pressure catalytic reduction of each glucosamine thus formed to the corresponding glucamine, and (c) reaction of the resultant secondary amines with CS2 to form the dithiocarboxy derivatives. Each compound was evaluated as an antagonist of acute cadmium (Cd) toxicity and as a complexing agent for intracellular metallothionein-bound Cd (Cd-MT) in mice. N-Benzyl-N-dithiocarboxy-D-glucamine (BDCG) was used as a positive control compound. Each congener afforded partial or complete protection against the lethal effects of 10.0 mg/kg CdCl2.2.5 H2O, and retarded accumulation of Cd in livers and kidneys when given 2 h after the acutely toxic dose of Cd. Each derivative was also effective in mobilizing Cd from MT-bound sites in livers and kidneys of mice which had received a sub-lethal dose of CdCl2 along with 109CdCl2 2 weeks earlier. Excretion of mobilized Cd was almost exclusively by the fecal route. Potency of the analogs, as well as the octanol/aqueous partition coefficients, increased with the overall length of the N-(n-alkyl) carbon chain. Each compound readily complexed Cd from partially purified Cd-MT in vitro. Serum Cd from mice treated with BDCG was associated principally with proteins of high molecular weight.

Synthesis of 14C-meglumine salicylate and its disposition in humans after oral administration.

The synthesis of 14C-meglumine salicylate was accomplished by heating 14C-meglumine with salicylic acid, in equimolar ratios, in 2-propanol. The average radiochemical yield was 97.5%. Ten healthy adult male volunteers were given 1.2 g of the compound orally. Five took 1.2 g of 1-deoxy-1-[14C]-methylamino-D-glucitol salicylate (containing about 47 micronCi), and five others took 1.2 g of 1-deoxy-1-methylamino-D-[U-14 micronCi), and five others took 1.2 g of 1-deoxy-1-methylamino-D-[U-14C]-glucitol salicylate (containing about 45 micronCi). Urine and feces were collected for 5 days, and blood was sampled for 24 hr. The peak urinary excretion of meglumine and/or its metabolites occurred between 4 and 8 hr after administration (about 7.2% of the administered dose). Meglumine was excreted primarily in the feces (72.4% over 5 days) and, to a smaller extent, in urine (21.3% over 5 days). No activity was detected in blood. The excretion rate and percentage excreted were the same for both groups of subjects, suggesting that meglumine was not metabolized by N-demethylation or conversion to carbon dioxide. The highest blood salicylate level, 44.4 +/- 1.9 microng/ml, was observed 1 hr after administration. Urinary levels of salicylic acid and its metabolites were observed to be at a maximum at 8 hr. Total salicylate recovery was 94.7 +/- 1.5% in 48 hr. Salicyluric acid was the major metabolite, accounting for 69.5 +/- 3.6% of the dose. Salicylic acid accounted for 6.8 +/- 1.2%.